Antonella Sistigu
Istituto di Patologia Generale,
Dipartimento di Medicina e Chirurgia Traslazionale
Università Cattolica del Sacro Cuore
Antonella Sistigu has not added Biography.
If you are Antonella Sistigu and would like to personalize this page please email our Author Liaison for assistance.
Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting.
Cytokine & growth factor reviews 08, 2017 | Pubmed ID: 28595838
Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.
Oncoimmunology , 2017 | Pubmed ID: 28638743
The added value of type I interferons to cytotoxic treatments of cancer.
Cytokine & growth factor reviews 08, 2017 | Pubmed ID: 28693974
Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
Cancer immunology research 06, 2018 | Pubmed ID: 29622580
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy.
Trends in cell biology 05, 2019 | Pubmed ID: 30765144
Assessment of IFN-γ and granzyme-B production by in "sitro" technology.
Methods in enzymology , 2020 | Pubmed ID: 31948559
Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies.
Methods in enzymology , 2020 | Pubmed ID: 32000907
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Journal for immunotherapy of cancer 03, 2020 | Pubmed ID: 32209603
Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade.
Cells 04, 2020 | Pubmed ID: 32290265
Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening.
Frontiers in immunology , 2020 | Pubmed ID: 33193295
Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers.
Emerging topics in life sciences Dec, 2017 | Pubmed ID: 33525801
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Cell death and differentiation Feb, 2021 | Pubmed ID: 33531658
The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition.
Cancers Apr, 2021 | Pubmed ID: 33921638
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.
Biology Sep, 2021 | Pubmed ID: 34571733
Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?
Biology Sep, 2021 | Pubmed ID: 34571790
The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure.
Cells Sep, 2021 | Pubmed ID: 34572009
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Nature immunology Sep, 2022 | Pubmed ID: 36002648
Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Cell death and differentiation May, 2023 | Pubmed ID: 37100955
3D cancer models: One step closer to human studies.
Frontiers in immunology , 2023 | Pubmed ID: 37114038
Epigenetics behind tumor immunology: a mini review.
Oncogene Sep, 2023 | Pubmed ID: 37604925
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Journal of translational medicine Nov, 2023 | Pubmed ID: 37996891
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry.
Methods in molecular biology (Clifton, N.J.) , 2024 | Pubmed ID: 38070104
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved